0000950170-24-074605.txt : 20240618 0000950170-24-074605.hdr.sgml : 20240618 20240618091518 ACCESSION NUMBER: 0000950170-24-074605 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240617 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Shareholder Nominations Pursuant to Exchange Act Rule 14a-11 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240618 DATE AS OF CHANGE: 20240618 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Tivic Health Systems, Inc. CENTRAL INDEX KEY: 0001787740 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 814016391 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41052 FILM NUMBER: 241050337 BUSINESS ADDRESS: STREET 1: 47685 LAKEVIEW BLVD CITY: FREMONT STATE: CA ZIP: 94538 BUSINESS PHONE: (888)276-6888 MAIL ADDRESS: STREET 1: 47685 LAKEVIEW BLVD CITY: FREMONT STATE: CA ZIP: 94538 8-K 1 tivc-20240617.htm 8-K 8-K
false000178774000017877402024-06-172024-06-170001787740dei:FormerAddressMember2024-06-172024-06-17

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 17, 2024

 

 

Tivic Health Systems, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-41052

81-4016391

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

47685 Lakeview Blvd.

 

 

Fremont, California

 

94538

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 888 276-6888

 

 

25821 Industrial Blvd., Suite 100

Hayward, California 94545

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.0001 per share

 

TIVC

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Appointment of Christina Valauri to the Board

On June 17, 2024, the board of directors (the “Board”) of Tivic Health Systems, Inc. (the “Company”) appointed Christina Valauri as a director of the Company, effective July 1, 2024, to fill a vacancy in the Class I class of directors of the Board. Additionally, Ms. Valauri was appointed to serve as a member of the Compensation Committee, Audit and Risk Committee and Nominations and Corporate Governance Committee of the Board, and will replace Karen Drexler as chairperson of the Nominations and Corporate Governance Committee, in each case effective July 1, 2024. Ms. Drexler will continue to serve as a member of the Nominations and Corporate Governance Committee upon Ms. Valauri taking over the chair of such committee.

Ms. Valauri has served as an advisor to the Company and the Board since April 2023.

There is no arrangement or understanding between Ms. Valauri and any other person pursuant to which Ms. Valauri was selected as a director of the Company. Other than the Company’s formal plan for compensating its non-executive directors for their services, there are no plans, contracts or arrangements or amendments to any plans, contracts or arrangements, that were entered into with Ms. Valauri in connection with her election to the Board, nor were there any equity grants or awards issued, or expected to be issued, to Ms. Valauri in connection therewith. Ms. Valauri is not a participant in, nor is she to be a participant in, any related-person transaction or proposed related-person transaction required to be disclosed by Item 404(a) of Regulation S-K under the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

Resignation of Karen Drexler from the Board

On June 17, 2024, Karen Drexler tendered her resignation from the Board and each of the Compensation Committee, Audit and Risk Committee and Nominations and Corporate Governance Committee thereof, in each case effective September 30, 2024. Ms. Drexler’s decision to resign from her positions as a director on the Company’s Board was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices, and it is expected that Ms. Drexler will continue to serve as an advisor to the Company and the Board after her resignation is effective.

Item 5.08 Shareholder Director Nominations

The Company has established August 9, 2024 as the date of the Company’s 2024 annual meeting of stockholders (the “Annual Meeting”), and June 17, 2024 as the record date for determining stockholders entitled to notice of, and to vote at, the Annual Meeting. The time, place and detailed information regarding the proposals to be presented at the Annual Meeting will be set forth in a Definitive Proxy Statement on Schedule 14A to be filed with the Securities and Exchange Commission.

Because the date of the Annual Meeting will be more than 30 days from the anniversary of the Company’s 2023 annual meeting of stockholders, the deadline for submission of proposals by stockholders for inclusion in the Company’s proxy materials in accordance with Rule 14a-8 under the Exchange Act will be 5:00 p.m. Pacific Time on Thursday, June 27, 2024. Any such proposal must also meet the requirements set forth in the rules and regulations of the Exchange Act in order to be eligible for inclusion in the proxy materials for the Annual Meeting.

In addition, in accordance with the Company’s amended and restated bylaws, as amended (“Bylaws”), any stockholder who intends to nominate a person for election as a director or submit a proposal for inclusion at the Company’s Annual Meeting must provide notice (“Stockholder Notice”) on or before 5:00 p.m. Pacific Time on Thursday, June 27, 2024. Any Stockholder Notice must comply with the specific requirements set forth in the Company’s Bylaws in order to be considered at the Annual Meeting. Any such proposal shall be mailed to: Tivic Health Systems, Inc., 47685 Lakeview Blvd, Fremont, CA 94538, Attn.: Secretary.

Item 7.01 Regulation FD Disclosure.

On June 18, 2024, the Company issued a press release announcing the changes to the Board discussed in Item 5.02, above. A copy of that press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this “Current Report”) and incorporated herein by reference.

The information set forth under Item 7.01 of this Current Report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of such section. The information in Item 7.01 of this Current Report, including Exhibit 99.1, shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any incorporation by reference language in any such filing, except as expressly set forth by specific reference in such a filing. This Current Report will not be deemed an admission as to the materiality of any information in this Current Report that is required to be disclosed solely by Regulation FD.

Forward-Looking Statements

This Current Report, including Exhibit 99.1 attached hereto, contains certain forward-looking statements that involve substantial risks and uncertainties. When used herein, the terms “anticipates,” “expects,” “estimates,” “believes,” “will” and similar expressions, as they relate to us or our management, are intended to identify such forward-looking statements.

Forward-looking statements in this Current Report, or hereafter, including in other publicly available documents filed with the Securities and Exchange Commission, reports to the stockholders of the Company and other publicly available statements issued or released by us involve known and unknown risks, uncertainties and other factors which could cause our actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. Such future results are based upon management’s best estimates based upon current conditions and the most recent results of operations. These risks include, but are not limited to, the risks set forth herein and in such other documents filed with the Securities and Exchange Commission, each of which could adversely affect our business and the accuracy of the forward-looking statements contained herein. Our actual results, performance or achievements may differ materially from those expressed or implied by such forward-looking statements.

Item 9.01 Financial Statements and Exhibits.

(d)

Exhibits.

Exhibit
No.

Description

99.1

Press Release, dated June 18, 2024.

104

Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101).

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

TIVIC HEALTH SYSTEMS, INC.

 

 

 

 

Date:

June 18, 2024

By:

/s/ Jennifer Ernst

 

 

 

Name: Jennifer Ernst
Title: Chief Executive Officer

 

 EX-99.1 2 tivc-ex99_1.htm EX-99.1 EX-99.1

 

Exhibit 99.1

 

 

PRESS RELEASE img553027_0.jpg

 

 

Tivic Health: Christina Valauri Appointed to Board of Directors

 

Wall Street Capital Markets Veteran and Recognized All-Star Bio-Medical Technology Analyst joins Tivic Health’s Governance Team

 

SAN FRANCISCO – June 18, 2024 – Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, is pleased to welcome Christina Valauri to its board of directors, effective July 1, 2024.

 

Ms. Valauri has served as a strategic advisor to the company since April 2023, and brings over 30-years of experience as a seasoned capital markets professional with extensive analytical and management experience. Ms. Valauri has a proven track record as a senior healthcare analyst, US and Global Head of Equity Research, senior broker-dealer manager, strategic business consultant, and board director and advisor. As a managing director and senior manager within capital markets, she has successfully developed and executed transformational business strategies in the US and internationally to drive growth, and provide enhanced operating performance and comprehensive regulatory and supervisory oversight. She has held leadership roles at US and international firms, including as the Global Director of Research at Cantor Fitzgerald, and senior research management roles at Credit Lyonnais, ING and Natixis.

 

Ms. Valauri’s career in equity securities research expands the Tivic boards’ deep expertise in pharmaceutical, biotech, and med-tech industries. She has extensive experience identifying and analyzing the commercial potential of breakthrough innovations, as well as mentoring and advising C-suite teams of private and public early-stage healthcare companies through product development, regulatory, go-to-market strategies, potential mergers and acquisitions, and IPOs.

 

Ms. Valauri currently serves as an Entrepreneur in Residence at Weill Cornell Medicine BioVenture eLab, where she applies her skills and experience in life sciences and business. She supports and facilitates the organization’s mission to foster an entrepreneurial ecosystem related to the innovations of researchers and clinicians. Ms. Valauri is the founder and CEO of Sagestone Advisory, LLC., and also serves as a senior advisor with Hanover International, Inc. and Astia.org. She has been recognized by The Wall Street Journal’s “Best on The Street” All-Star Analyst Survey and has received the Award for Excellence in Medical Education Public

 

 

Affairs - Association of American Medical Colleges. Ms. Valauri earned her BA in Biology from Reed College and an MBA from Cornell University.

 

“Over the past year, as an advisor to our Board and the company, Christina Valauri has demonstrated deep commitment to excellence and the highest standards of ethical governance. This, paired with her insight into capital markets and deep background in research analysis, is a powerful combination to help ensure we make the best decisions for the company, our customers and our shareholders,” stated Sheryle Bolton, Chair of the Board.

 

“I could not be more excited that Christina has agreed to serve on our board of directors, particularly as we forge new segments in our bioelectronic portfolio, focused on precision modulation of vagus nerve activity,” shared Jennifer Ernst, Chief Executive Officer of Tivic Health.

 

Additionally, independent director, Karen Drexler, tendered her resignation from the board and the committees thereof, effective September 30, after which she will be continuing with the company as a strategic advisor. Ms. Drexler previously served as an advisor to the company from August 2017 through August 2019 when she joined Tivic Health’s board as the company’s first independent director. Ernst continued, “Karen was an instrumental force in the early formation of Tivic Health. I deeply appreciate her commitment to Tivic Health’s development for the past eight years and her continued support as a strategic advisor to the company.”

About Tivic Health

Tivic Health is a commercial health tech company advancing the field of bioelectronic medicine. Tivic Health’s patented technology platform leverages stimulation on the trigeminal, sympathetic, and vagus nerve structures. Tivic Health’s non-invasive and targeted approach to the treatment of inflammatory chronic health conditions gives consumers and providers drug-free therapeutic solutions with high safety profiles, low risk, and broad applications. Tivic Health’s first commercial product ClearUP is an FDA approved, award-winning, handheld bioelectronic sinus device. ClearUP is clinically proven, doctor-recommended, and is available through online retailers and commercial distributors. For more information visit http://tivichealth.com @TivicHealth

 

Forward-Looking Statements

This press release may contain “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Tivic Health Systems, Inc.’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Actual results could differ materially from those

 

 

contained in any forward-looking statement as a result of various factors, including, without limitation: statements regarding the expansion of Tivic Health’s product portfolio; changes in board composition; Ms. Drexler’s service as an advisor to the company; market and other conditions; macroeconomic factors, including inflation; and unexpected costs, charges or expenses that reduce Tivic Health’s capital resources. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Tivic Health’s actual results to differ from those contained in the forward-looking statements, see Tivic Health’s filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 29, 2024, under the heading “Risk Factors”; as well as the company’s subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and Tivic Health Systems, Inc. undertakes no duty to update such information except as required by applicable law.

 

 

 

Media Contact:

Morgan Luke

Morgan.Luke@tivichealth.com

 

Investor Contact:

Hanover International, Inc.

ir@tivichealth.com

 

 GRAPHIC 3 img553027_0.jpg GRAPHIC begin 644 img553027_0.jpg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end EX-101.SCH 4 tivc-20240617.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Entity Ex Transition Period Entity File Number Entity Incorporation, State or Country Code Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications Document Information [Table] Document Information [Line Items] Former Address [Member] Entity Addresses, Address Type [Axis] Address Type [Domain] XML 6 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Document And Entity Information
Jun. 17, 2024
Document Information [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 17, 2024
Entity Registrant Name Tivic Health Systems, Inc.
Entity Central Index Key 0001787740
Entity Emerging Growth Company true
Entity File Number 001-41052
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 81-4016391
Entity Address, Address Line One 47685 Lakeview Blvd.
Entity Address, City or Town Fremont
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94538
City Area Code 888
Local Phone Number 276-6888
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Ex Transition Period false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol TIVC
Security Exchange Name NASDAQ
Former Address [Member]  
Document Information [Line Items]  
Entity Address, Address Line One 25821 Industrial Blvd., Suite 100
Entity Address, City or Town Hayward
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94545
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( .A)TE@'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " #H2=)8S[E0_.\ K @ $0 &1O8U!R;W!S+V-O&ULS9)1 M2\,P$,>_BN2]O:;5(:'+BV-/"H(#Q;>0W+9@DX;DI-VW-ZU;A^@'\#%W__SN M=W"M#D+W$9]C'S"2Q70SNLXGH<.:'8F" $CZB$ZE,B=\;N[[Z!3E9SQ 4/I# M'1#JJEJ!0U)&D8()6(2%R&1KM- 1%?7QC#=ZP8?/V,TPHP$[=.@I 2\Y,#E- M#*>Q:^$*F&"$T:7O IJ%.%?_Q,X=8.?DF.R2&H:A')HYEW?@\/;T^#*O6UB? M2'F-^5>R@DX!U^PR^;5YV.RV3-95?5M4JX+?[W@C^)W@]?OD^L/O*NQZ8_?V M'QM?!&4+O^Y"?@%02P,$% @ Z$G26)E&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" #H2=)80I?S,/ $ N%0 & 'AL+W=ODJ.!WLWTIB^$+4 3VW(E&<*W M[\H&FU[-FMQ,WR0V6 \_K5;/KGR]D>I5KS@WY"T*8]UW5L8D5XV&]E<\8OI" M)CR&;Q921U1#SDOK$2#/ZM^8B'H54"CK]WHD[Q MFW;@X?5>_3Z;/$QFSC0?R?"+",RJ[_0<$O %2T/S(CAMM7S9:BSOV23 M/]MJ.<1/M9'1;C 01"+._[.W72 .!] C ^AN ,VX\Q_**&^988-K)3=$V:=! MS5YD4\U& YR([:I,C8)O!8PS@UOIIQ!D0X9Q0.YB(\R6C.-\M2%JUPT#/V(? M;?@[P9MU256IT#KH(*[9'_A2Z&-8L#XS*)*,%QG)M;")P^ MD@\P'F8_DE'"XDHX7,^H%,NVRP+K\A2L>Q%R\IQ& MR#B 3!,+X><^>SR(-9(]"*+K=9J7'D98U@ /=>P]X3 (P*]A=^TN2%8&/L75 ML<,E6]U.KTT>V2M?V][A)EP'V(;U2OOW< /_EG5D[V"M9W)374YQN7O%(QD; M#*TL"A[NZM^B%7DX47(M8K\ZCKCF:(BAE77"P^W]6[2)U 8,[T^1'-\VH2NI<*&ZAL,K:X"'&_A4AL(7QI:E)TAO)5A8 MR8.KU/'0L@10W*0GBI_[$!X.^ROO"Z$UXXI\6BRJUZ]&KY:L]'V*F_1_R,9: MIT!6"XC+U@(>M/XGV?[=&YE!@Z9%5I/R3K*2"U>KY2HMGN*>/!,&.@RY(![] M>?X+F7(_A7U0V??4*-E] W.:&NF_GI&$*;)F8821E'9/<7/>APS6UE^Q>,F/-M\U0L_#Z>WP M=XRIM'F*N[0]Y4.X][W%UR=N';;Z?(DJ?>B5(XP('-YTT+]_5S-9IH/]_JY&D7HYUKM*K;&P=LO^R;Q MB=E#J28A7X"0>]$%!U'YR[G\QL@D>R$VE\;(*+M<<08ESSX WR^D-/L;^XZM M>$4Z^ =02P,$% @ Z$G26)^@&_"Q @ X@P T !X;"]S='EL97,N M>&ULW5=M:]LP$/XK0C]@;F)JXI$8MD!AL(U"\V%?E5AV!'KQ9+ES^NNGLVPG M:75EW8>QS:')W3VZNT=W)YFN6W>2_.'(N2.]DKK=T*-SS?LD:0]'KEC[SC1< M>Z0R5C'G55LG;6,Y*UMP4C)9WMQDB6)"TV*M.W6G7$L.IM-N0V]H4JPKH\^6 ME :#7\H4)X],;NB62;&W8EC+E)"G8%Z"X6"DL<1Y*GQ#%V!IGP*\"!JP'.,H MH8T%8Q(RA._]N/P9,&FM5X64,\$E#89BW3#GN-5W7AD6#\87$!GEW:GQ#&O+ M3HOE+3T[##\^R=[8DMLYS8).IF(M>05TK*B/\.M,DP#HG%%>* 6KC68#A\EC M%'S8 Y?R 5KXK;J*W5B'_2^FO-CT1=X=-8T\O1!BEHK'O;^RPF+-9O\R-%8 M\>2SP:0)P:?EA6;/CO9NFJ:]PSLM_D/.?K7/--;=,7I+VH_\W M5_DMC)/Q]%PZC+N.HL?X;[:)'-M[#/)73)>UYN1]76 M^T$D7O!9QP<&%Y_J?]K-#]! SCMHHB*]1G MA?H$KQBR'3Y8GKA/[I_X3O,\3;,,J^AV&V6PQ>J69? 7CX9Q P\L#V1Z6ZWQ M;N,3\OH<8#U];4*PG>*3B.T4KS4@\;J!1Y['NXWE 0^L"]CL0/YX'IBIN$^: M0ERHY_U=3_ 102P,$% @ Z$G26)>*NQS $P( L M !?3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:(7->=I3W;+T]!;X"O.DQQ0FE(2S,. M\,W2?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_'36TGHX-R#8._AE8P=S8\?=_<#4$L#!!0 ( .A)TE@D M'INBK0 /@! : >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'.UD3T. M@S ,A:\2Y0 U4*E#!4Q=6"LN$ 7S(Q(2Q:X*MR^% 9 Z=&&RGBU_[\E.GV@4 M=VZ@MO,D1FL&RF3+[.\ I%NTBB[.XS!/:A>LXEF&!KS2O6H0DBBZ0=@S9)[N MF:*'3^ 5!+ P04 " #H M2=)899!YDAD! #/ P $P %M#;VYT96YT7U1Y<&5S72YX;6RMDTU.PS 0 MA:\295LE+BQ8H*8;8 M=< %C3QJK_I-G6M+;,T[:2J 2%85-K'C>O,^>EZS> MCQ&PZ)WUV)0=47P4 E4'3F(=(GBNM"$Y2?R:MB)*M9-;$/?+Y8-0P1-XJBA[ ME.O5,[1R;ZEXZ7D;3?!-FI6.5Z*U .EK >MKBRAE#VQH%.JB]XY8: M8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*$3FQ!'_'G2/)W55D(TADIJ]X M(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87_QO.\1'"[K\_L;S63AI_YHOA M/UY_ 5!+ 0(4 Q0 ( .A)TE@'04UB@0 +$ 0 " M 0 !D;V-0&UL4$L! A0#% @ Z$G26,^Y4/SO M*P( !$ ( !KP &1O8U!R;W!S+V-O&UL4$L! A0# M% @ Z$G26)E&PO=V]R:W-H965T&UL4$L! A0# M% @ Z$G26)^@&_"Q @ X@P T ( !- T 'AL+W-T M>6QE&PO=V]R:V)O;VLN>&UL4$L! A0#% M @ Z$G26"0>FZ*M ^ $ !H ( !9A( 'AL+U]R96QS M+W=O9(9 0 SP, M !, ( !2Q, %M#;VYT96YT7U1Y<&5S72YX;6Q02P4& / D "0 ^ @ E10 end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 2 23 1 false 1 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://www.tivichealthsystems.com/20240617/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports tivc-20240617.htm tivc-20240617.xsd http://xbrl.sec.gov/dei/2024 false false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tivc-20240617.htm": { "nsprefix": "tivc", "nsuri": "http://www.tivichealthsystems.com/20240617", "dts": { "inline": { "local": [ "tivc-20240617.htm" ] }, "schema": { "local": [ "tivc-20240617.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 1, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2024": 2 }, "contextCount": 2, "entityCount": 1, "segmentCount": 1, "elementCount": 29, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 27 }, "report": { "R1": { "role": "http://www.tivichealthsystems.com/20240617/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_895da04c-f86e-42f2-a8fe-8d0fcdb82ba7", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "tivc-20240617.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_895da04c-f86e-42f2-a8fe-8d0fcdb82ba7", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "tivc-20240617.htm", "first": true, "unique": true } } }, "tag": { "dei_AddressTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AddressTypeDomain", "presentation": [ "http://www.tivichealthsystems.com/20240617/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Address Type [Domain]", "documentation": "An entity may have several addresses for different purposes and this domain represents all such types." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://www.tivichealthsystems.com/20240617/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://www.tivichealthsystems.com/20240617/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.tivichealthsystems.com/20240617/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "presentation": [ "http://www.tivichealthsystems.com/20240617/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.tivichealthsystems.com/20240617/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://www.tivichealthsystems.com/20240617/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.tivichealthsystems.com/20240617/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.tivichealthsystems.com/20240617/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.tivichealthsystems.com/20240617/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.tivichealthsystems.com/20240617/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityAddressesAddressTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressesAddressTypeAxis", "presentation": [ "http://www.tivichealthsystems.com/20240617/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Addresses, Address Type [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.tivichealthsystems.com/20240617/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.tivichealthsystems.com/20240617/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.tivichealthsystems.com/20240617/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r9" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://www.tivichealthsystems.com/20240617/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.tivichealthsystems.com/20240617/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://www.tivichealthsystems.com/20240617/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.tivichealthsystems.com/20240617/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_FormerAddressMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "FormerAddressMember", "presentation": [ "http://www.tivichealthsystems.com/20240617/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Former Address [Member]", "documentation": "Former address for entity" } } }, "auth_ref": [ "r6", "r7" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://www.tivichealthsystems.com/20240617/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.tivichealthsystems.com/20240617/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.tivichealthsystems.com/20240617/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://www.tivichealthsystems.com/20240617/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://www.tivichealthsystems.com/20240617/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://www.tivichealthsystems.com/20240617/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://www.tivichealthsystems.com/20240617/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://www.tivichealthsystems.com/20240617/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r8" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "249", "Section": "308", "Subsection": "a" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 8-K", "Number": "249", "Section": "308" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 14 0000950170-24-074605-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-074605-xbrl.zip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end XML 16 tivc-20240617_htm.xml IDEA: XBRL DOCUMENT 0001787740 2024-06-17 2024-06-17 0001787740 dei:FormerAddressMember 2024-06-17 2024-06-17 false 0001787740 8-K 2024-06-17 Tivic Health Systems, Inc. DE 001-41052 81-4016391 47685 Lakeview Blvd. Fremont CA 94538 888 276-6888 25821 Industrial Blvd., Suite 100 Hayward CA 94545 false false false false Common Stock, par value $0.0001 per share TIVC NASDAQ true false